---
provider: perplexity
model: sonar-pro
cached: false
start_time: '2025-11-15T18:33:37.107443'
end_time: '2025-11-15T18:33:51.603503'
duration_seconds: 14.5
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: low
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 10
---

## Question

Research the ITIH2 (ITIH2) gene in human, focusing on its molecular function, biological processes, and cellular localization. Include information about protein domains, known interactions, and any disease associations.

## Output

The **ITIH2 gene** encodes the inter-alpha-trypsin inhibitor heavy chain 2, a protein primarily involved in extracellular matrix (ECM) stabilization, with roles in inflammation, tumor suppression, and disease processes[1][5][6].

---

### 1. Key Concepts and Definitions

- **Molecular Function:**  
  ITIH2 acts as a **serine-type endopeptidase inhibitor** and binds to **hyaluronan**, a major ECM component, helping stabilize the matrix and regulate cell migration and tissue integrity[1][6][3]. It is also involved in **endopeptidase inhibitor activity**[1][9].

- **Biological Processes:**  
  ITIH2 participates in:
  - **ECM stabilization** by covalently linking to hyaluronan, mediated by TSG-6[5][10].
  - **Regulation of inflammation**: ITIH2 is downregulated during acute inflammation, acting as a negative acute phase protein[5].
  - **Tumor suppression**: ITIH2 is frequently downregulated in solid tumors (breast, colon, lung), suggesting a role in inhibiting tumor growth and metastasis[2][5].
  - **Cell migration and tissue remodeling**: ITIH2 is upregulated during wound healing and involved in angiogenesis[5].
  - **Response to exogenous stressors**: ITIH2 is a hub gene in hepatotoxicity models, indicating a role in cellular stress responses[8].

- **Cellular Localization:**  
  ITIH2 is a **secreted plasma protein** found in the **extracellular space**, especially in tissues rich in ECM such as the liver, kidney, and various brain regions[6][7][9]. It is detected in urine, especially in disease states like SLE[4].

---

### 2. Protein Domains

- **Gla Domain:**  
  ITIH2 contains a **Gla (gamma-carboxyglutamic acid) domain**, which requires vitamin K-dependent post-translational modification and is involved in calcium binding[3].
- **Heavy Chain Domain:**  
  The heavy chain domain enables covalent linkage to hyaluronan and interaction with other ECM proteins[5][10].

---

### 3. Known Interactions

- **Hyaluronan:**  
  ITIH2 binds and stabilizes hyaluronan in the ECM, often via TSG-6-mediated transfer[5][10].
- **TSG-6:**  
  TSG-6 catalyzes the transfer of ITIH2 heavy chains to hyaluronan, forming HC-HA complexes crucial for ECM integrity and inflammation[5].
- **Other Matrix Proteins:**  
  ITIH2 may interact with cell surface proteins and other ECM components, influencing cell adhesion and migration[6].
- **Protein-Protein Interactions:**  
  ITIH2 is identified as a hub protein in several interaction networks, especially in stress and toxicity responses[8].

---

### 4. Disease Associations

- **Cancer:**  
  ITIH2 is **downregulated in multiple solid tumors** (breast, colon, lung), correlating with loss of tumor suppressor activity and increased invasiveness[2][5]. Its expression is strongly associated with estrogen receptor status in breast cancer[2][5].
- **Systemic Lupus Erythematosus (SLE):**  
  Urinary ITIH2 levels correlate with SLE activity and renal damage, suggesting a role as a biomarker for lupus nephritis[4].
- **Thrombophilia Due to HRG Deficiency and Skeletal Tuberculosis:**  
  These are listed as disease associations, though the mechanistic link is less well defined[1].
- **Psychiatric Disorders:**  
  Genetic studies suggest ITIH2 may share risk factors with schizophrenia and depression, though mechanisms remain under investigation[5].
- **CNS Tumors:**  
  ITIH2 is expressed in low-grade CNS cancers and normal brain tissue but absent in highly invasive glioblastomas, indicating a possible anti-invasive function[5].

---

### 5. Recent Developments and Latest Research (2023–2024)

- **Tumor Suppression:**  
  Recent studies reinforce ITIH2’s role as a tumor suppressor, with strong evidence of downregulation in solid tumors and its involvement in ECM stabilization to inhibit tumor growth[5].
- **Inflammation and Acute Phase Response:**  
  ITIH2 is now recognized as a negative acute phase protein, downregulated during inflammation, with contrasting regulation compared to other ITIH family members[5].
- **SLE Biomarker:**  
  2023–2024 research highlights ITIH2 as a promising urinary biomarker for SLE activity and kidney involvement[4].
- **Cellular Stress Response:**  
  ITIH2’s role as a hub gene in hepatotoxicity models suggests broader involvement in cellular responses to toxicants[8].

---

### 6. Current Applications and Real-World Implementations

- **Cancer Diagnostics:**  
  ITIH2 expression profiling is used in breast cancer tissue arrays to correlate with estrogen receptor status and tumor grade[2][5].
- **SLE Monitoring:**  
  Urinary ITIH2 measurement is being explored as a non-invasive marker for lupus nephritis activity[4].
- **Toxicology:**  
  ITIH2 is studied as a hub gene in models of hepatotoxicity, potentially aiding in the assessment of drug-induced liver injury[8].

---

### 7. Expert Opinions and Analysis

- **Tumor Suppressor Role:**  
  Experts increasingly view ITIH2 and related ITIH family members as critical ECM stabilizers and tumor suppressors, with loss of expression linked to increased malignancy and invasiveness[2][5].
- **Inflammation Modulation:**  
  ITIH2’s dual role in inflammation (negative acute phase protein) and tissue repair is seen as central to its biological significance[5].
- **Biomarker Potential:**  
  The correlation of ITIH2 with disease activity in SLE and cancer supports its utility as a biomarker in clinical diagnostics[4][5].

---

### 8. Relevant Statistics and Data

- **Breast Cancer:**  
  Loss of ITIH2 expression was confirmed in **70% of breast cancer cases** (n=50), with strong correlation to estrogen receptor expression (p < 0.001)[2].
- **SLE:**  
  ITIH2 and ECM1 levels in urine show significant correlation with disease activity and renal damage in SLE patients[4].

---

### URLs and Publication Dates

- [GeneCards ITIH2 summary](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ITIH2) (accessed 2024)
- [Frontiers in Medicine review](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1432224/full) (published 2024)
- [Wiley SLE biomarker study](https://onlinelibrary.wiley.com/doi/full/10.1002/jcla.24622) (published 2023)
- [PMC cancer study](https://pmc.ncbi.nlm.nih.gov/articles/PMC2268946/) (published 2008, cited for foundational data)
- [UniProt ITIH2 entry](https://www.uniprot.org/uniprotkb/P19823/entry) (accessed 2024)
- [Ma'ayan Lab ITIH2 interactions](https://maayanlab.cloud/Harmonizome/gene/ITIH2) (accessed 2024)

---

**Summary:**  
ITIH2 is a secreted ECM protein with serine protease inhibitor activity, crucial for matrix stabilization, inflammation modulation, and tumor suppression. It contains a Gla domain, interacts with hyaluronan via TSG-6, and is downregulated in several cancers and inflammatory diseases. Recent research highlights its biomarker potential in SLE and its broader role in cellular stress responses.

## Citations

1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ITIH2
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2268946/
3. https://en.wikipedia.org/wiki/ITIH2
4. https://onlinelibrary.wiley.com/doi/full/10.1002/jcla.24622
5. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1432224/full
6. https://www.uniprot.org/uniprotkb/P19823/entry
7. https://www.proteinatlas.org/ENSG00000151655-ITIH2
8. https://maayanlab.cloud/Harmonizome/gene/ITIH2
9. https://geneglobe.qiagen.com/us/knowledge/gene/ENSG00000151655
10. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=3698